KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2016 - 2025)

Teva Pharmaceutical Industries' Cash & Equivalents history spans 17 years, with the latest figure at $3.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 7.76% year-over-year to $3.6 billion, compared with a TTM value of $3.6 billion through Dec 2025, up 7.76%, and an annual FY2025 reading of $3.6 billion, up 7.76% over the prior year.
  • Cash & Equivalents for Q4 2025 was $3.6 billion at Teva Pharmaceutical Industries, up from $2.2 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $3.6 billion in Q4 2025, with the low at $1.7 billion in Q1 2025.
  • Average Cash & Equivalents over 5 years is $2.5 billion, with a median of $2.2 billion recorded in 2022.
  • Year-over-year, Cash & Equivalents soared 47.58% in 2024 and then tumbled 43.26% in 2025.
  • Tracing TEVA's Cash & Equivalents over 5 years: stood at $2.2 billion in 2021, then rose by 29.38% to $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then rose by 2.29% to $3.3 billion in 2024, then increased by 7.76% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Cash & Equivalents are $3.6 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.2 billion (Q2 2025).